Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs by Choy, E et al.
ORIGINAL RESEARCH
Indirect Treatment Comparison of the Efficacy
and Safety of Sarilumab Monotherapy in Rheumatoid
Arthritis Patients with Inadequate Response
to Conventional Disease-Modifying Antirheumatic
Drugs
Ernest Choy . Nick Freemantle . Clare Proudfoot . Chieh-I Chen .
Laurence Pollissard . Andreas Kuznik . Hubert van Hoogstraten .
Erin Mangan . Paulo Carita . Thi-Minh-Thao Huynh
Received: December 20, 2018 / Published online: March 12, 2019
 The Author(s) 2019
ABSTRACT
Introduction: To evaluate the comparative
efficacy and safety of subcutaneous sarilumab
200 mg monotherapy administered every
2 weeks (q2w) versus other monotherapies of
biologic, targeted and conventional synthetic
disease-modifying antirheumatic drugs
(bDMARDs, tsDMARDs, csDMARDs) at recom-
mended doses for treatment of rheumatoid
arthritis in patients who are intolerant of or
inadequate responders to csDMARDs
(csDMARD-IR).
Methods: A systematic literature review and
network meta-analysis (NMA) were conducted
on 24-week efficacy outcomes: Health Assess-
ment Questionnaire Disability Index (HAQ-DI)
score, American College of Rheumatology
(ACR) 20/50/70 criteria, and European League
Against Rheumatism Disease Activity Score
28-joint count erythrocyte sedimentation rate
(DAS28) \ 2.6. In addition, serious infections
and serious adverse events (SI/SAE) were exam-
ined at 24 weeks.
Results: Nine trials were selected for the NMA.
Sarilumab 200 mg showed superiority versus
adalimumab monotherapy on all efficacy out-
comes and versus tofacitinib monotherapy on
ACR20. Compared with csDMARDs, sarilumab
200 mg showed superiority on ACR 20/50/70
criteria and DAS28\2.6 but had similar efficacy
on HAQ-DI. Efficacy of sarilumab 200 mg was
similar versus certolizumab, etanercept, tofaci-
tinib and tocilizumab 8 mg/kg monotherapy
across all efficacy outcomes. SI/SAE appeared
similar for sarilumab 200 mg versus all
comparators.
Conclusion: In csDMARD-IR patients, sar-
ilumab 200 mg monotherapy has superior effi-
cacy and similar safety versus csDMARDs,
superior efficacy and similar safety versus adal-
imumab, and similar efficacy and safety versus
bDMARDs and tsDMARDs.
Enhanced Digital Features To view enhanced digital
features for this article go to: https://doi.org/10.6084/
m9.figshare.7712498.
Electronic supplementary material The online
version of this article (https://doi.org/10.1007/s12325-
019-00912-x) contains supplementary material, which is
available to authorized users.
E. Choy
Cardiff University, Cardiff, UK
N. Freemantle
University College London, London, UK
C. Proudfoot
Formerly of Sanofi, Guildford, UK
C.-I. Chen  A. Kuznik  E. Mangan
Regeneron Pharmaceuticals, Inc., Tarrytown, NY,
USA
L. Pollissard  P. Carita  Thi-Minh-ThaoHuynh (&)
Sanofi France, Chilly-Mazarin, France
e-mail: Thi-Minh-Thao.Huynh@sanofi.com
H. van Hoogstraten
Sanofi, Bridgewater, NJ, USA
Adv Ther (2019) 36:817–827
https://doi.org/10.1007/s12325-019-00912-x
Funding: Sanofi and Regeneron Pharmaceuti-
cals, Inc.
Keywords: Biologic disease-modifying antirh-
eumatic drugs; Network meta-analysis; Rheu-
matoid arthritis; Rheumatology; Sarilumab
monotherapy
INTRODUCTION
Sarilumab, a human monoclonal antibody,
which blocks both the soluble and membrane
forms of the interleukin-6 receptor, is a biologic
disease-modifying antirheumatic drug
(bDMARD) for use as monotherapy or in com-
bination with conventional synthetic (cs)
DMARDs for the treatment of adults with
moderate-to-severe rheumatoid arthritis (RA) in
patients who are intolerant or inadequate
responders to csDMARDs (csDMARD-IR) [1–4].
Evaluation of the comparative effectiveness and
safety of sarilumab against other DMARDs is
needed to guide evidence-based medicine [5];
however, there are limited head-to-head data
comparing sarilumab with other relevant RA
treatments. In the absence of direct evidence, a
network meta-analysis (NMA) facilitates evalu-
ation of sarilumab against other treatments
using a combination of direct and indirect trial
data. This NMA was conducted to evaluate the
comparative efficacy and safety of subcutaneous
(SC) sarilumab 200 mg monotherapy, adminis-
tered every 2 weeks (q2w) versus other globally
approved monotherapies for RA. Comparator
treatments included bDMARDs, targeted syn-
thetic DMARDs (tsDMARDs) and csDMARDs at
their recommended doses for the treatment of
RA as monotherapy for csDMARD-IR. Compar-
ative evidence of sarilumab in combination
with csDMARDs is published elsewhere [6].
METHODS
A systematic literature review (SLR) and NMA
were conducted following methods in line with
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [7] and
recommended in the current National Institute
for Health and Care Excellence (NICE) specifica-
tion formanufacturer and sponsor submission of
evidence [8], aswell as the 2016NICE technology
appraisal of adalimumab, etanercept, infliximab,
certolizumab pegol, golimumab, tocilizumab,
and abatacept for RA [9]. Due to the nature of the
study it was not registered with clinicaltrials.gov
or a similar body. This article is based on previ-
ously conducted studies and does not contain
any studies with human participants or animals
performed by any of the authors.
Study Selection
Searches for the SLR were conducted in the
MEDLINE, EMBASE, and Cochrane databases
(all without any time limit), plus conference
proceedings since 2013 for evidence published
until December 6, 2016. Studies were selected
according to pre-defined population/interven-
tion/comparator/outcome/study design criteria
(Table 1) [7, 8, 10, 11]. All titles, abstracts and
articles were then screened independently by
two researchers, with study selection following
published best practice guidelines for indirect
treatment comparisons [8, 10, 11].
Data on study design, patient characteristics,
efficacy, safety and patient-reported outcomes at
the time points 12 (± 4), 24 (± 4) and 52 (± 8)
weeks forall studies (exceptopen-label extensions)
were extracted independently by two reviewers in
a pre-defined data extraction process. Evidence for
the NMA was filtered for drugs licensed for RA at
doses approved in Europe, the USA and Canada.
All trials comparing one intervention of interest
with at least one other intervention of interest or
methotrexateorC 1 csDMARD(s)were considered
in the evidence base.
Small studies have been shown to distort
meta-analyses [12] therefore, studies with fewer
than 30 patients per arm were excluded. Studies
which did not report any outcomes of interest
were also excluded.
Treatment Categorisation
Different licensed dosages and different routes of
administration [e.g., intravenous (IV) versus SC
delivery)] of the same treatment were pooled in
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many cases, on the basis of evidence of equiva-
lence (Supplementary Table S1). These decisions
were explored by examining forest plots of the
odds ratio (OR) for American College of
Rheumatology (ACR) 20% response criteria
(ACR20) at 24 weeks in individual studies by
groupof interventions. If the confidence intervals
were overlapping (e.g., as for infliximab studies),
the doses were pooled. The validity of the deci-
sions was also confirmed via clinician input.
Outcomes Examined
Key efficacy endpoints were extracted and ana-
lyzed including ACR20, ACR 50% response
criteria (ACR50), ACR 70% response criteria
(ACR70), and the Health Assessment Question-
naire Disability Index (HAQ-DI) change from
baseline. The European League Against
Rheumatism (EULAR) Disease Activity Score
28-joint count (DAS28) remission (defined as
DAS28 erythrocyte sedimentation rate or C-re-
active protein \ 2.6) was also extracted; how-
ever, this endpoint was not analyzed given that
the EULAR networks were small and a high level
of variability was observed in response rates
between the different studies. Safety endpoints
included the proportion of patients with any
serious infection (SI) and the proportion of
patients with any serious adverse event (SAE).
Table 1 Population/intervention/comparator/outcome/study design and search criteria for the SLR
Criteria Inclusion
Study design Randomized controlled trials above phase I (including crossover studies up to time of crossover)
Population Adult patients (aged C 18 years) with moderately-to-severely active RA who have had inadequate
response to C 1 csDMARDs
Adult patients (aged C 18 years) with moderately-to-severely active RA who have had inadequate
response to C 1 TNFa-inhibitors
Treatment/
intervention


























Comparator Placebo or any of the above listed treatments as monotherapy
Outcomes Efﬁcacy, safety and patient reported outcomes at 24 weeks (± 4 weeks) and 52 weeks (± 8 weeks)
Time No limit
Language English language
cs Conventional synthetic, DMARD disease-modifying antirheumatic drug, RA rheumatoid arthritis, TNF tumor necrosis
factor
a Only interventions with global regulatory approval were included
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All efficacy and safety outcomes were examined
at 24 weeks as this was the assessment period
with the most data available for analysis.
Network Meta-Analysis
Feasibility Assessment
Prior to the conduct of the NMA, a feasibility
assessment was conducted to assess the suffi-
ciency of the evidence base to draw feasible
networks for all outcomes of interest. The
exchangeability assumption is critical and
requires that selected trials measure the same
underlying relative treatment effects. Devia-
tions to this assumption can be evaluated
through two metrics: heterogeneity (i.e., evalu-
ation of comparability in characteristics and
results across included studies) and consistency
(i.e., evaluation of consistency between direct
and indirect evidence). Effect modifiers were
evaluated by establishing the link between
patient characteristics at baseline and ACR20;
only weight was identified as an effect modifier
given the expected variation in patient charac-
teristics across RA studies [11, 13, 14], which
can limit the validity of indirect comparisons.
Variability of response in the placebo arms is
an issue which can limit indirect comparisons,
and the heterogeneity of RA studies has been
previously noted [15] where the treatment effect
expressed as log ORs has a negative relationship
with the baseline risk [9, 16].While the common
comparator across most monotherapy trials was
an active comparator (adalimumab), for the few
placebo-controlled studies, variability was
therefore considered in the selection of models.
Bayesian NMA
The efficacy and safety of the treatments inclu-
ded in the analysis were evaluated using a
Bayesian NMA approach [10, 14, 17], compris-
ing a likelihood distribution, a model with
parameters and prior distributions for these
parameters. A linear model with normal likeli-
hood distribution was used for continuous
outcomes, and a binomial likelihood with a log
link was used for the dichotomous outcomes
[15, 18]. Consistent with NICE guidelines, flat
(non-informative) prior distributions were
assumed for nearly all outcomes so as not to
influence the observed results by the prior dis-
tribution [15]. Prior distributions of the baseline
treatments and relative treatment effects were
normal, with 0 mean and variance of 10,000,
with informative prior based on between study
variance according to the recommendation of
NICE in the case of limited data [15]. Random-
and fixed-effects models were evaluated to allow
for heterogeneity of treatment effects between
studies, with the choice of base-case informed
by Deviance Information Criterion (DIC) values
and mean total residual deviance (compared
against the number of fitted data points), as well
as consistency with directly reported trial results
[17]. Posterior densities for unknown parame-
ters were estimated using Markov chain Monte
Carlo simulations.
All results for OR-NMA and risk difference
(RD)-NMA were based on 100,000 iterations on
three chains, with a burn-in of 20,000 itera-
tions. Convergence was assessed by visual
inspection of trace plots. The accuracy of the
posterior estimates was assessed using the
Monte Carlo error for each parameter (Monte
Carlo error \ 1% of the posterior standard
deviation). All models were implemented using
WinBUGS. Results of the NMA are presented in
terms of ‘point estimates’ (median of posterior)
for the relative treatment effects, along with the
95% credible intervals.
Scenario Analyses
Two scenario analyses were conducted. The first
excluded studies conducted in exclusively Asian
populations (i.e., the SATORI, CHANGE and
Etanercept 309 studies) to test the potential
modifying effect of patient body weight (with
Asian ethnicity serving as a proxy for popula-
tions with relatively lower body weight than
other populations. For the second analysis,
tumour necrosis factor (TNF)-a inhibitors were
pooled together as a class. For the latter scenario
analysis, ACR outcomes were compared with
the base case which evaluated the TNF-a inhi-
bitors individually. This scenario was evaluated
to inform cost-effectiveness evaluations of
sarilumab.
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RESULTS
SLR Search and Selection
Following the SLR search a total of 31 citations
which met the screening criteria were retrieved
(Fig. 1); these reported the results of 19 ran-
domized clinical trials (RCTs). Five RCTs were
excluded because the comparator was out of
scope. Of the 14 RCTs which were included in
the NMA feasibility assessment, 5 of these were
excluded due to no outcomes of interest. A net
of 9 RCTs were included in the NMA (Fig. 1),
including the MONARCH trial of sarilumab
versus adalimumab monotherapy
(NCT02332590) [2].
Network Meta-Analysis Evidence Base
Evaluation of the evidence base indicated that
the ACR networks, and in particular ACR20
(Fig. 2), were the most robust networks where
Fig. 1 Systematic review and network meta-analyses study selection ﬂow chart. NMA Network meta-analysis
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most interventions included were frommultiple
trials.
Key features of patient demographics and
baseline data from the selected studies are pro-
vided in Supplementary Table S2. Among 9 tri-
als included, 4 were phase III trials, 1 each was a
phase II trial, phase II/III trial and phase IV trial;
the trial phase was not mentioned for the
remaining 2 trials. Study durations varied from
24 weeks up to 52 weeks; however, 1 dose-
ranging study of tofacitinib compared with
adalimumab was designed for cross-over to
tofacitinib at week 12 for patients in the adali-
mumab arm [19]. Therefore, this study was
included only for evaluating outcomes of
tofacitinib versus placebo and included in the
relevant networks. In 3 studies, patients had to
have been on stable methotrexate for at least
12 weeks prior to entering the study; in another
3 studies this criterion was not required, and in
the remaining studies no such information was
reported.
Sample sizes varied from fewer than 50
patients to more than 150 patients per ran-
domized group. Rescue medication was
permitted in 5 of the trials and not reported in
the remainder of the trials.
Base Case Model Choice
The feasibility assessment indicated that there
was considerably less variability where the
common comparator was an active comparator
(adalimumab), with some degree of variability
where placebo was the control arm. Therefore, a
fixed-effects model using conventional OR
model was selected as the base-case model for
ACR20/50/70 outcomes (ACR20: DIC = 141.98;
ACR50: DIC = 135.62; ACR70: DIC = 99.93).
For the continuous efficacy outcome, HAQ-DI, a
standard change from baseline NMA was con-
ducted. In addition, the RD-NMA was applied
for DAS28 \2.6 and safety outcomes due to
convergence issues in the OR model and/or due
to the relative rarity of the event.
Base Case Network Meta-Analysis Results
In the base case, NMA indicated superior effi-
cacy for sarilumab 200 mg versus adalimumab
monotherapy on all efficacy outcomes and
Fig. 2 Evidence base networks for American College of Rheumatology 20% response rate outcomes at 24 weeks. csDMARD
conventional synthetic disease-modifying antirheumatic drug
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versus tofacitinib monotherapy on ACR20
(Table 2). Compared with csDMARDs, sar-
ilumab 200 mg had superior efficacy on ACR
20/50/70 criteria and DAS28 \ 2.6 but had
similar efficacy versus csDMARDs on HAQ-DI.
Efficacy of sarilumab 200 mg was similar versus
certolizumab, etanercept, tofacitinib and tocili-
zumab 8 mg/kg monotherapy across all efficacy
outcomes. All safety outcomes appeared similar
for sarilumab 200 mg versus all comparator
monotherapies.
Scenario Analyses
After excluding the studies SATORI, CHANGE
and Etanercept 309, sarilumab 200 mg
monotherapy was found to be statistically
superior to placebo and adalimumab, and
comparable to certolizumab, etanercept, tocili-
zumab 8 mg/kg IV and tofacitinib monothera-
pies. For the scenario in which TNF-a inhibitors
treatments were pooled together, sarilumab
200 mg monotherapy was found to be statisti-
cally superior versus placebo, csDMARDs, TNF-a
inhibitors and tofacitinib. Compared with
tocilizumab 8 mg/kg IV, sarilumab efficacy was
comparable.
DISCUSSION
Active comparator-controlled, randomized tri-
als evaluating the comparative efficacy and
safety of bDMARDs and tsDMARDs for the
treatment of RA are few and limited to adali-
mumab as active comparator, including the
MONARCH study of sarilumab compared with
adalimumab [2, 20–24]. The objective of this
study was to evaluate the comparative efficacy
and safety of SC sarilumab 200 mg monother-
apy, administered q2w versus other globally
approved monotherapies for RA.
Consistent with the head-to-head trial of
sarilumab versus adalimumab in MONARCH,
the present NMA indicated that sarilumab
200 mg monotherapy had superior efficacy
versus adalimumab monotherapy on all out-
comes. It was also found that sarilumab had
superior efficacy versus tofacitinib monother-
apy on ACR20 and versus csDMARDs on ACR
20/50/70 criteria and DAS28\ 2.6. On other
outcomes for these monotherapies and against
all the other tsDMARD monotherapies, similar
efficacy was observed. Rates of SI/SAE for sar-
ilumab monotherapy were equivalent to those
of all bDMARD, tsDMARD and csDMARD
monotherapies.
These results are consistent with previously
published NMAs of the comparator bDMARD,
tsDMARD and csDMARD monotherapies in RA,
without sarilumab included in the networks
[25–27]. In a 2015 meta-analysis by Buckley
et al., it was found that patients receiving a TNF
inhibitor or tofacitinib had greater ACR 20/50/
70 responses than those receiving placebo [27].
While tocilizumab resulted in greater responses
than TNF inhibitor, these were not statistically
significant.
A more recent 2017 NMA of 28 studies
comparing biologic monotherapy versus
methotrexate, placebo or other biologic
monotherapy found that all agents, except
anakinra and infliximab, were superior to pla-
cebo [26]. Furthermore, etanercept and ritux-
imab were superior to anakinra and tocilizumab
was superior to adalimumab, anakinra, cer-
tolizumab, and golimumab. No differences were
found between etanercept, tocilizumab and
rituximab. A Cochrane review, updated in 2016,
compared the efficacy and safety of biologic or
tofacitinib monotherapy in patients who had
failed traditional DMARDs [25]. The analysis of
46 RCTs found that overall, biologic therapy
was superior to placebo and methotrexate/other
DMARDs. TNF inhibitor and non-TNF inhibitor
showed similar efficacy. However, anakinra and
tofacitinib showed similar results for HAQ as
placebo.
Strengths and Limitations
One limitation of the study was the variability
in placebo response observed across the net-
work; however, given the large number of
active-controlled trials for the monotherapy
csDMARD-IR population, it was feasible to
address this situation by conducting OR-NMA
[15, 28].
824 Adv Ther (2019) 36:817–827
In addition, some of the comparative studies
of etanercept, certolizumab pegol and tofaci-
tinib required 2 intermediate comparators
rather than 1, thus creating a greater degree of
uncertainty.
The strengths of this NMA include the range
of efficacy and safety outcomes which have
been considered, providing a comprehensive
view of the comparative efficacy and safety of
sarilumab to inform clinical decision-making
and the conduct of health technology assess-
ments. The most robust networks, ACR20/50,
used only one common comparator on all
comparisons with sarilumab on these end-
points. The scenario analyses confirmed the
results against the base case analysis, where
comparisons were feasible.
The present indirect comparison was con-
ducted following best practice guidelines and
demonstrated that sarilumab SC 200 mg
monotherapy has superior efficacy compared
with adalimumab, as well as csDMARDs alone,
and comparable or better efficacy and similar
safety compared with other bDMARDs and
tsDMARDs in the csDMARD-IR patient popula-
tions. Compared with tocilizumab 8 mg/kg IV,
sarilumab 200 mg had similar efficacy and
safety.
CONCLUSION
In csDMARD-IR patients, sarilumab 200 mg
monotherapy has superior efficacy and similar
safety versus csDMARDs, superior efficacy and
similar safety versus adalimumab, and similar
efficacy and safety versus bDMARDs and
tsDMARDs.
ACKNOWLEDGEMENTS
We thank the participants of the original stud-
ies included in this analysis. The authors would
also like to thank Parexel for conducting the
literature searches and analyses.
Funding. This study, the article processing
charges and open access fee were sponsored by
Sanofi and Regeneron Pharmaceuticals, Inc. The
sponsor was involved in the study design, col-
lection, analysis and interpretation of data, as
well as data checking of information provided
in the manuscript. The authors received no
honoraria related to the development of this
publication. All authors had full access to all of
the data in this study and take complete
responsibility for the integrity of the data and
accuracy of the data analysis.
Medical Writing and Editorial Assis-
tance. Medical writing assistance and editorial
support, under the direction of the authors,
were provided by Gauri Saal, MA Economics,
and Sinead Stewart, both of Prime (Knutsford,
UK), funded by Sanofi/Regeneron Pharmaceu-
ticals according to Good Publication Practice
guidelines (http://www.ismpp.org/gpp3).
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Disclosures. Ernest Choy has received
research grants, and consultancy and speaker
fees, from Amgen, Biogen, Bristol Myer Scripps,
Boehringer Ingelheim, Celgene, Chugai
Pharma, Eli Lilly, Janssen, Novimmune, Novar-
tis, Pfizer, Regeneron Pharmaceuticals, Inc.,
Roche, R-Pharm, Sanofi, Tonix and UCB. Thi-
Minh-Thao Huynh is an employee of Sanofi and
holds stock and/or stock options in the com-
pany. Laurence Pollissard is an employee of
Sanofi and holds stock and/or stock options in
the company. Hubert van Hoogstraten is an
employee of Sanofi and holds stock and/or stock
options in the company. Paulo Carita is an
employee of Sanofi and holds stock and/or stock
options in the company. Clare Proudfoot is a
former employee and current stockholder of
Sanofi, and current employee of Novartis.
Chieh-I Chen is an employee of Regeneron
Pharmaceuticals, Inc., and holds stock and/or
stock options in the company. Andreas Kuznik
is an employee of Regeneron Pharmaceuticals,
Inc., and holds stock and/or stock options in
Adv Ther (2019) 36:817–827 825
the company. Erin Mangan is an employee of
Regeneron Pharmaceuticals, Inc., and holds
stock and/or stock options in the company.
Nick Freemantle has received consulting fees
from Sanofi, Novo Nordisk, Ipsen, Allergan,
Takeda, Biogen, Abbvie and Lifecell.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
Data Availability. The datasets generated
during and/or analysed during the current
study are not publicly available as the sponsor-
ing companies do not publicly share datasets,
but are available from the corresponding author
on reasonable request.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Genovese MC, Fleischmann R, Kivitz AJ, Rell-
Bakalarska M, Martincova R, Fiore S, et al. Sar-
ilumab plus methotrexate in patients with active
rheumatoid arthritis and inadequate response to
methotrexate: results of a phase III study. Arthritis
Rheumatol. 2015;67(6):1424–37.
2. Burmester GR, Lin Y, Patel R, van Adelsberg J,
Mangan EK, Graham NM, et al. Efficacy and safety
of sarilumab monotherapy versus adalimumab
monotherapy for the treatment of patients with
active rheumatoid arthritis (MONARCH): a ran-
domised, double-blind, parallel-group phase III
trial. Ann Rheum Dis. 2017;76(5):840–7.
3. Strand V, Kosinski M, Chen CI, Joseph G, Rendas-
Baum R, Graham NM, et al. Sarilumab plus
methotrexate improves patient-reported outcomes
in patients with active rheumatoid arthritis and
inadequate responses to methotrexate: results of a
phase III trial. Arthritis Res Ther. 2016;18:198.
4. Fleischmann R, van Adelsberg J, Lin Y, Castelar-
Pinheiro GD, Brzezicki J, Hrycaj P, et al. Sarilumab
and nonbiologic disease-modifying antirheumatic
drugs in patients with active rheumatoid arthritis
and inadequate response or intolerance to tumor
necrosis factor inhibitors. Arthritis Rheumatol.
2017;69(2):277–90.
5. Epstein D. The use of Comparative Effectiveness
Research and Health Technology Assessment in
European countries: current situation and prospects
for the future. www.ugr.es/*davidepstein/HTA%
20in%20european%20countries.docx. Accessed 27
Feb 2017.
6. Huynh T, Proudfoot C, Chen C, Pollissard L, Kuznik
A, van Hoogstraten H, et al. Network meta-analysis
of the efficacy and safety of sarilumab monotherapy
and combination therapy in rheumatoid arthritis
patients with intolerance or inadequate response to
disease-modifying antirheumatic drugs. J Manag
Care Spec Pharm. 2017;23:S75.
7. Hutton B, Salanti G, Caldwell DM, Chaimani A,
Schmid CH, Cameron C, et al. The PRISMA exten-
sion statement for reporting of systematic reviews
incorporating network meta-analyses of health care
interventions: checklist and explanations. Ann
Intern Med. 2015;162(11):777–84.
8. National Institute for Health and Care Excellence.
Guide to the methods of technology appraisal 2013.
https://www.nice.org.uk/process/pmg9/resources/
guide-to-the-methods-of-technology-appraisal-2013-
pdf-2007975843781. Accessed 27 Feb 2017.
9. National Institute for Health and Care Excellence.
Adalimumab, etanercept, infliximab, certolizumab
pegol, golimumab, tocilizumab and abatacept for
rheumatoid arthritis not previously treated with






failed-82602790920133. Accessed 27 Feb 2017.
10. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A,
Hawkins N, et al. Interpreting indirect treatment
comparisons and network meta-analysis for health-
care decision making: report of the ISPOR Task
Force on Indirect Treatment Comparisons Good
Research Practices: part 1. Value Health.
2011;14(4):417–28.
11. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler
R, Cappelleri JC, et al. Conducting indirect-treat-
ment-comparison and network-meta-analysis
826 Adv Ther (2019) 36:817–827
studies: report of the ISPOR Task Force on Indirect
Treatment Comparisons Good Research Practices:
part 2. Value Health. 2011;14(4):429–37.
12. Nuesch E, Trelle S, Reichenbach S, Rutjes AW,
Tschannen B, Altman DG, et al. Small study effects
in meta-analyses of osteoarthritis trials: meta-epi-
demiological study. BMJ. 2010;341:c3515.
13. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The
results of direct and indirect treatment comparisons
in meta-analysis of randomized controlled trials.
J Clin Epidemiol. 1997;50(6):683–91.
14. Lu G, Ades AE. Combination of direct and indirect
evidence in mixed treatment comparisons. Stat
Med. 2004;23(20):3105–24.
15. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU
Technical Support Document 3: Heterogeneity:




16. Machado DA, Guzman RM, Xavier RM, Simon JA,
Mele L, Pedersen R, et al. Open-label observation of
addition of etanercept versus a conventional dis-
ease-modifying antirheumatic drug in subjects with
active rheumatoid arthritis despite methotrexate
therapy in the Latin American region. J Clin
Rheumatol. 2014;20(1):25–33.
17. Caldwell DM, Ades AE, Higgins JP. Simultaneous
comparison of multiple treatments: combining
direct and indirect evidence. BMJ. 2005;331(7521):
897–900.
18. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde
A. Bayesian measures of model complexity and fit.
J R Stat Soc B. 2002;64:583–639.
19. Fleischmann R, Cutolo M, Genovese MC, Lee EB,
Kanik KS, Sadis S, et al. Phase IIb dose-ranging study
of the oral JAK inhibitor tofacitinib (CP-690,550) or
adalimumab monotherapy versus placebo in
patients with active rheumatoid arthritis with an
inadequate response to disease-modifying anti-
rheumatic drugs. Arthritis Rheum. 2012;64(3):
617–29.
20. Weinblatt ME, Schiff M, Valente R, van der Heijde
D, Citera G, Zhao C, et al. Head-to-head compar-
ison of subcutaneous abatacept versus adalimumab
for rheumatoid arthritis: findings of a phase IIIb,
multinational, prospective, randomized study.
Arthritis Rheum. 2013;65(1):28–38.
21. Gabay C, Emery P, van Vollenhoven R, Dikranian
A, Alten R, Pavelka K, et al. Tocilizumab
monotherapy versus adalimumab monotherapy for
treatment of rheumatoid arthritis (ADACTA): a
randomised, double-blind, controlled phase 4 trial.
Lancet. 2013;381(9877):1541–50.
22. Schiff M, Weinblatt ME, Valente R, van der Heijde
D, Citera G, Elegbe A, et al. Head-to-head compar-
ison of subcutaneous abatacept versus adalimumab
for rheumatoid arthritis: two-year efficacy and
safety findings from AMPLE trial. Ann Rheum Dis.
2014;73(1):86–94.
23. van Vollenhoven RF, Fleischmann R, Cohen S, Lee
EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or
adalimumab versus placebo in rheumatoid arthritis.
N Engl J Med. 2012;367(6):508–19.
24. Taylor PC, Keystone EC, van der Heijde D, Weinblatt
ME, Del Carmen Morales L, Reyes Gonzaga J, et al.
Baricitinib versus placebo or adalimumab in rheuma-
toid arthritis. N Engl J Med. 2017;376(7):652–62.
25. Singh JA, Hossain A, Tanjong Ghogomu E, Mudano
AS, Tugwell P, Wells GA. Biologic or tofacitinib
monotherapy for rheumatoid arthritis in people
with traditional disease-modifying anti-rheumatic
drug (DMARD) failure: a cochrane systematic
review and network meta-analysis (NMA).
Cochrane Database Syst Rev 2016;11:Cd012437.
26. Tarp S, Furst DE, Dossing A, Ostergaard M, Loren-
zen T, Hansen MS, et al. Defining the optimal bio-
logical monotherapy in rheumatoid arthritis: a
systematic review and meta-analysis of randomised
trials. Semin Arthritis Rheum. 2017;46(6):699–708.
27. Buckley F, Finckh A, Huizinga TW, Dejonckheere F,
Jansen JP. Comparative efficacy of novel DMARDs
as monotherapy and in combination with
methotrexate in rheumatoid arthritis patients with
inadequate response to conventional DMARDs: a
network meta-analysis. J Manag Care Spec Pharm.
2015;21(5):409–23.
28. National Institute for Clinical and Economic
Review. Targeted immune modulators for rheuma-
toid arthritis: effectiveness and value. Evidence
report. https://icer-review.org/wp-content/uploads/
2016/08/NE_CEPAC_RA_Evidence_Report_FINAL_
040717.pdf. Accessed 7 Nov 2017.
Adv Ther (2019) 36:817–827 827
